DKT international Tanzania has launched Injecta-Fem, a World Health Organisation (WHO)-prequalified inject-able contraceptive, marking a major step forward in expanding reproductive health options for women across the country.

Speaking over the weekend in Dar es Salaam during the launch ceremony, which brought together healthcare professionals, policymakers, and reproductive health advocates, DKT Tanzania country manager Navid Adatia said Injecta-Fem addresses a critical unmet need for modern contraceptive methods in Tanzania.

Adatia emphasised that   the   new   contraceptive   option is discreet, convenient, and suitable for a wide range of   women—including   post-partum    and    breastfeeding mothers after six weeks, as well as women living with HIV or on antiretroviral therapy.

"For too long, women in Tanzania have faced limited access   to   high-quality   and   affordable contraceptive options,” Adatia said. "Injecta-Fem empowers women with choices that align with their lifestyles and health needs."

He added that DKT Tanzania has been working to overcome barriers to contraceptive access    through social marketing and clinical partnerships, offering a wide range of reproductive health products such as condoms, implants,    emergency    contraception, and intrauterine devices. 

Injecta-Fem is a 150mg medroxyprogesterone acetate intramuscular injection that provides     effective contraception for up to 12 weeks.  It works by preventing ovulation and thickening cervical mucus, offering more than 99 percent effectiveness when administered on schedule. 

The launch of Injecta-Fem is seen as a critical milestone in improving women's health and expanding access to family planning services in Tanzania.